R
Ryan C. Lynch
Researcher at Fred Hutchinson Cancer Research Center
Publications - 50
Citations - 826
Ryan C. Lynch is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Transplantation. The author has an hindex of 11, co-authored 50 publications receiving 460 citations. Previous affiliations of Ryan C. Lynch include Washington University in St. Louis & University of Washington.
Papers
More filters
Journal ArticleDOI
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Alexandre V. Hirayama,Jordan Gauthier,Kevin A. Hay,Kevin A. Hay,Jenna M. Voutsinas,Qian Wu,Ted Gooley,Daniel Li,Sindhu Cherian,Xueyan Chen,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Utkarsh Acharya,Utkarsh Acharya,Ryan D. Cassaday,Ryan D. Cassaday,Aude G. Chapuis,Aude G. Chapuis,Tejaswini Dhawale,Paul C. Hendrie,Hans-Peter Kiem,Hans-Peter Kiem,Ryan C. Lynch,Ryan C. Lynch,J L Ramos,J L Ramos,Mazyar Shadman,Mazyar Shadman,Brian G. Till,Brian G. Till,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +37 more
TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.
Journal ArticleDOI
Hodgkin lymphoma, version 2.2020
Richard T. Hoppe,Ranjana H. Advani,Weiyun Z. Ai,Richard F. Ambinder,Philippe Armand,Celeste M. Bello,Cecil M. Benitez,Philip J. Bierman,Kirsten M Boughan,Bouthaina S. Dabaja,Leo I. Gordon,Francisco J. Hernandez-Ilizaliturri,Alex F. Herrera,Ephraim P. Hochberg,Jiayi Huang,Patrick B. Johnston,Mark S. Kaminski,Vaishalee P. Kenkre,Nadia Khan,Ryan C. Lynch,Kami J. Maddocks,Jonathan McConathy,Matthew McKinney,Monika L. Metzger,David S. Morgan,Carolyn Mulroney,Rachel Rabinovitch,Karen C. Rosenspire,Stuart Seropian,Randa Tao,Jane N. Winter,Joachim Yahalom,Jennifer L. Burns,Ndiya Ogba +33 more
TL;DR: The introduction of less toxic and more effective regimens has significantly advanced HL cure rates and this portion of the NCCN Guidelines focuses on the management of classic HL.
Journal ArticleDOI
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Victor A. Chow,Ajay K. Gopal,Ajay K. Gopal,Ajay K. Gopal,David G. Maloney,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle,Cameron J. Turtle,Stephen D. Smith,Stephen D. Smith,Stephen D. Smith,Chaitra S. Ujjani,Chaitra S. Ujjani,Chaitra S. Ujjani,Mazyar Shadman,Mazyar Shadman,Mazyar Shadman,Ryan D. Cassaday,Ryan D. Cassaday,Ryan D. Cassaday,Brian G. Till,Brian G. Till,Brian G. Till,Yolanda D. Tseng,Edus H. Warren,Edus H. Warren,Edus H. Warren,Andrei R. Shustov,Andrei R. Shustov,Andrei R. Shustov,Manoj Menon,Manoj Menon,Sandra Bhark,Sandra Bhark,Utkarsh Acharya,Erin Mullane,Lindsay M. Hannan,Lindsay M. Hannan,Lindsay M. Hannan,Jenna M. Voutsinas,Ted Gooley,Ryan C. Lynch,Ryan C. Lynch,Ryan C. Lynch +45 more
TL;DR: The results show clear trends in age-related complications in treatment-naive patients with thalassaemia intermedia and serum ferritin level and morbidity risk in transfusion-independent patients with beta-thalassemia intermedia: the ORIENT study.
Journal ArticleDOI
Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy
Stephen D. Smith,Stephen D. Smith,Brian G. Till,Mazyar Shadman,Ryan C. Lynch,Ryan C. Lynch,Andrew J. Cowan,Andrew J. Cowan,Qian Wu,Jenna M. Voutsinas,Heather Rasmussen,Katherine Blue,Chaitra S. Ujjani,Chaitra S. Ujjani,Andrei R. Shustov,Andrei R. Shustov,Ryan D. Cassaday,Ryan D. Cassaday,Jonathan R. Fromm,Ajay K. Gopal,Ajay K. Gopal +20 more
TL;DR: Evaluation of PD‐L1 as a biomarker to identify DLBCL patients who may benefit from this first‐line strategy supports historical data, and pembrolizumab can be added to R‐CHOP, and is associated with a high CR rate and 2‐year PFS.
Journal ArticleDOI
Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.
Kenneth R. Carson,Kenneth R. Carson,Peter A. Riedell,Ryan C. Lynch,Chadi Nabhan,Tanya M. Wildes,Weijian Liu,Weijian Liu,Arun Ganti,Ryan Roop,Ryan Roop,Kristen M. Sanfilippo,Kristen M. Sanfilippo,Katiuscia O'Brian,Katiuscia O'Brian,Jingxia Liu,Nancy L. Bartlett,Amanda F. Cashen,Nina D. Wagner-Johnston,Todd A. Fehniger,Graham A. Colditz +20 more
TL;DR: Results suggest that full dose anthracycline therapy may be less important in the treatment of diffuse large B-cell lymphoma patients over age 80, and the low frequency of completion of full dose intensity treatment suggests that standard doses are an unrealistic standard of care for patients this age.